Alpha 2.0
Login Register
» Authors » Jerry W Snidow

Jerry W Snidow

Explore the profile of Jerry W Snidow including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 68
Followers 0
Related Specialties
Psychiatry
Neurology
Infectious Diseases
Top 10 Co-Authors
John Wurzelmann
Amy Pierce
Eric R Mortensen
Christi S Kleoudis
Jaime E Hernandez
Gary E Pakes
George E Bigelow
Richard Rauck
Susan M Mitchell
John H Wakeford
Published In
J Pain
BMC Infect Dis
Am J Addict
Pharmacotherapy
Affiliations
Soon will be listed here.
Recent Articles
1.
A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain
Jansen J, Lorch D, Langan J, Lasko B, Hermanns K, Kleoudis C, et al.
J Pain . 2011 Feb; 12(2):185-93. PMID: 21292169
Unlabelled: Gastrointestinal (GI) side effects are common with opioid medication, and constipation affects ∼40% of patients. Such symptoms considerably impair patients' quality of life. Alvimopan is an orally administered, systemically...
2.
A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain
Irving G, Penzes J, Ramjattan B, Cousins M, Rauck R, Spierings E, et al.
J Pain . 2011 Feb; 12(2):175-84. PMID: 21292168
Unlabelled: The balance between the pain relief provided by opioid analgesics and the side effects caused by such agents is of particular significance to patients who take opioids for the...
3.
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
Swindells S, Cohen C, Berger D, Tashima K, Liao Q, Pobiner B, et al.
BMC Infect Dis . 2005 Apr; 5:23. PMID: 15819974
Background: Hydroxyurea (HU) is an immunomodulatory agent that has been documented to enhance the antiretroviral activity of nucleoside reverse transcriptase inhibitors, such as abacavir (ABC) and didanosine (ddI), and would...
4.
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
Keiser P, Sension M, DeJesus E, Rodriguez A, Olliffe J, Williams V, et al.
BMC Infect Dis . 2005 Jan; 5:2. PMID: 15647105
Background: Hyperlipidemia secondary to protease inhibitors (PI) may abate by switching to anti-HIV medications without lipid effects. Method: An open-label, randomized pilot study compared changes in fasting lipids and HIV-1...
5.
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects
Hendrix C, Wakeford J, Wire M, Lou Y, Bigelow G, Martinez E, et al.
Pharmacotherapy . 2004 Oct; 24(9):1110-21. PMID: 15460171
Study Objective: To investigate the steady-state pharmacokinetics of methadone enantiomers when coadministered with amprenavir. Design: Prospective, open-label, within-subject pharmacokinetic study. Setting: University research center. Subjects: Nineteen opioid-dependent, methadone-maintained, healthy individuals...
6.
The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects
Rainey P, Friedland G, Snidow J, McCance-Katz E, Mitchell S, Andrews L, et al.
Am J Addict . 2002 Mar; 11(1):66-74. PMID: 11876585
Methadone pharmacokinetics were determined in an open-label, within subject study in 16 methadone-maintained, non-HIV-infected subjects prior to and following administration of one lamivudine 150-mg/zidovudine 300-mg combination tablet to determine whether...